In the clinic, immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) exhibit a potent and durable anti-tumor activity in LUAD patients [10]. This evidence concerns the gene PDCD1 and neoplasm.